Financial Projections
DCF model and financial forecasts
Overview
This section presents NuBatt's financial projections for the period 2027-2031, based on the Company's discounted cash flow (DCF) model.
CRITICAL DISCLAIMER - PLEASE READ CAREFULLY
The financial projections in this section are estimates based on assumptions that are likely to prove incorrect. Investors should understand:
- No Revenue History: The Company has no material historical revenue to support these projections
- No Committed Contracts: There are no binding customer contracts for any revenue stream
- Unproven Technology: Products have not been manufactured or sold at commercial scale
- Regulatory Dependency: Revenue cannot commence until regulatory approvals are obtained (not yet secured)
- High Uncertainty: Actual results will likely differ materially from these projections
THESE PROJECTIONS SHOULD NOT BE RELIED UPON AS INDICATIVE OF FUTURE PERFORMANCE.
Important Notice: The financial projections contained herein are forward-looking statements based on current expectations and assumptions. Actual results may differ materially. Prospective investors should carefully review the Risk Factors section of this Memorandum.
Projection Basis and Limitations
| Factor | Status | Risk |
|---|---|---|
| Customer Contracts | None committed | Revenue timing highly uncertain |
| Manufacturing Facility | Not yet built | Construction delays could affect timeline |
| Regulatory Approvals | Not yet obtained | Revenue cannot commence without licenses |
| Production Yields | Unproven at scale | Margin assumptions may prove incorrect |
| Market Acceptance | Untested | Demand may not materialise as projected |
| Competition | Emerging | Market share assumptions may be optimistic |
Revenue Projections
Summary Revenue Forecast
Revenue CAGR (2027-2031): ~170%
| Year | Revenue | YoY Growth |
|---|---|---|
| 2027 | $50M | — |
| 2028 | $201M | 301% |
| 2029 | $661M | 229% |
| 2030 | $1.41B | 113% |
| 2031 | $2.85B | 102% |
Revenue by Stream
| Stream | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|
| Nuclear Batteries | $5M | $50M | $250M | $500M | $1.2B |
| Medical Isotopes | $30M | $50M | $101M | $351M | $600M |
| Industrial Isotopes | $10M | $61M | $121M | $200M | $350M |
| Nuclear Waste Recycling | — | — | $140M | $291M | $545M |
| Advanced Carbon Materials | $3M | $25M | $30M | $40M | $81M |
| Technology Licensing | $2M | $15M | $20M | $30M | $71M |
| Total | $50M | $201M | $661M | $1.41B | $2.85B |
Revenue Mix Evolution
| Stream | Percentage |
|---|---|
| Nuclear Batteries | 10% |
| Medical Isotopes | 60% |
| Industrial Isotopes | 20% |
| Nuclear Waste Recycling | 0% |
| Advanced Carbon Materials | 6% |
| Technology Licensing | 4% |
Profitability Projections
EBITDA Forecast
| Year | Revenue | EBITDA | EBITDA Margin |
|---|---|---|---|
| 2027 | $50M | $12M | 24.0% |
| 2028 | $201M | $85M | 42.3% |
| 2029 | $661M | $300M | 45.4% |
| 2030 | $1.41B | $621M | 44.0% |
| 2031 | $2.85B | $1.23B | 43.2% |
Gross Margin Trajectory
| Year | Gross Margin | Driver |
|---|---|---|
| 2027 | ~40% | Pilot production, lower volumes |
| 2028 | ~45% | Production scaling begins |
| 2029 | ~50% | Manufacturing efficiencies |
| 2030 | ~52% | Volume economics |
| 2031 | ~55% | Optimised operations |
Path to Profitability
Investment (2026): Capital deployment, facility build-out
Revenue Ramp (2027): First revenues, positive EBITDA
Scale (2028-2029): Rapid revenue growth, margin expansion
Maturity (2030-2031): Optimised operations, significant profitability
Cost Structure
Operating Expense Breakdown
| Category | 2027 | 2031 (Target) | Commentary |
|---|---|---|---|
| Cost of Goods Sold | ~60% | ~45% | Scale economics improve |
| R&D | ~15% | ~8% | Ongoing product development |
| Sales & Marketing | ~10% | ~8% | Customer acquisition |
| G&A | ~15% | ~7% | Administrative leverage |
Key Cost Drivers
| Cost Category | Description | Management Approach |
|---|---|---|
| Isotope Sourcing | Raw materials for batteries and isotope sales | Multiple suppliers, waste recycling |
| SiC Materials | Semiconductor materials | Internal production capability |
| Facility Operations | Manufacturing, hot cells, cleanrooms | Scale efficiencies |
| Personnel | Engineering, operations, commercial | Selective hiring, productivity focus |
| Regulatory | Licensing, compliance, safety | Invest in expertise |
Personnel Costs
| Year | Headcount | Total Payroll (incl. benefits) |
|---|---|---|
| 2026/Y1 | 16 | $4.2M |
| 2027/Y2 | 37 | $8.6M |
| 2028/Y3 | 71 | $17.8M |
| 2029/Y4 | 114 | $30.4M |
| 2030/Y5 | 172 | $51.3M |
| 2031/Y6 | 261 | $86.4M |
Capital Expenditure
CapEx Summary
| Period | Amount | Primary Use |
|---|---|---|
| Year 1 | $66M | Facility construction, core equipment, hot cells |
| Year 2 | $15.6M | Expansion equipment, production scale-up |
| Year 3+ | Variable | Capacity expansion as needed |
CapEx Allocation (Year 1)
Manufacturing Facility (~50%)
~$33M
Production Equipment (~25%)
~$16.5M
Hot Cells & Shielding (~15%)
~$10M
Cleanroom & Labs (~10%)
~$6.5M
Facility Requirements
| Capability | Purpose |
|---|---|
| Cleanroom | Semiconductor and electronics manufacturing |
| Hot Cells | Isotope handling and battery integration |
| Testing Labs | Quality assurance and validation |
| Shielded Storage | Isotope inventory management |
| Office/Admin | Team workspace |
Working Capital
Working Capital Components
| Component | Considerations |
|---|---|
| Inventory | Isotope inventory, semiconductor materials, finished goods |
| Accounts Receivable | Defence payment cycles (60-90 days), commercial terms |
| Accounts Payable | Supplier payment terms |
| Cash Reserves | Operating buffer, contingency |
Working Capital Assumptions
| Metric | Assumption |
|---|---|
| Days Sales Outstanding | 60-90 days (defence), 30-45 days (commercial) |
| Days Inventory | 90-120 days (isotope lead times) |
| Days Payable | 45-60 days |
| Cash Buffer | 3-6 months operating expenses |
Valuation Framework
DCF Model Parameters
| Parameter | Value | Rationale |
|---|---|---|
| WACC | 12% | Risk-adjusted for early-stage nuclear technology |
| Terminal Growth Rate | 3% | Long-term GDP-aligned growth |
| Tax Rate | 17% | Singapore corporate tax rate |
| Projection Period | 5 years | 2027-2031 |
Valuation Implications
Post-Money Valuation: ~$397M with 30% equity offered for $119M investment
| Metric | Value |
|---|---|
| Pre-Money Valuation | ~$278M |
| Investment Amount | $119M |
| Post-Money Valuation | ~$397M |
| Equity Offered | 30% |
Exit Opportunities
IPO
Target 2030 at $10B+ valuation at scale
Strategic Acquisition
Opportunistic — Defence, aerospace, energy majors
Secondary Sale
Ongoing liquidity for early investors
Key Assumptions
Sensitivity Analysis
Revenue Sensitivity
| Scenario | 2029 Revenue | 2031 Revenue | Key Drivers |
|---|---|---|---|
| Base Case | $661M | $2.85B | Plan assumptions |
| Conservative (-20%) | $529M | $2.28B | Slower market adoption |
| Optimistic (+20%) | $793M | $3.42B | Faster contract wins |
EBITDA Sensitivity
| Scenario | 2029 EBITDA | 2031 EBITDA | Margin |
|---|---|---|---|
| Base Case | $300M | $1.23B | 43.2% |
| Conservative | $240M | $985M | 34.6% |
| Optimistic | $360M | $1.48B | 51.9% |
Key Sensitivities
| Factor | Impact of +/-10% Change |
|---|---|
| Revenue Growth Rate | High impact on valuation |
| Gross Margin | Moderate impact on EBITDA |
| CapEx Requirements | Moderate impact on cash flow |
| Working Capital Intensity | Lower impact |
Royalty Obligation
NDB License Royalty
| Aspect | Terms |
|---|---|
| Rate | 2% of after-tax profit |
| Applicability | Products using licensed NDB patents |
| NuBatt-Owned IP | No royalty on products using only NuBatt patents |
| Calculation | Applied to net profit after corporate tax |
Royalty Impact Estimate
| Year | Est. After-Tax Profit | Royalty (2%) |
|---|---|---|
| 2027 | ~$9M | ~$180K |
| 2028 | ~$49M | ~$1M |
| 2029 | ~$186M | ~$3.7M |
| 2030 | ~$461M | ~$9.2M |
| 2031 | ~$920M | ~$18.4M |
Note: Royalty applies only to products incorporating licensed NDB technology. Products using only NuBatt-owned patents are royalty-free.
Cash Flow Profile
Cash Flow Summary
| Year | Operating CF | CapEx | Free Cash Flow |
|---|---|---|---|
| 2026 | Negative | ($66M) | Negative |
| 2027 | ~$5M | ($15.6M) | Negative |
| 2028 | ~$40M | ~($10M) | ~$30M |
| 2029 | ~$180M | ~($20M) | ~$160M |
| 2030 | ~$450M | ~($30M) | ~$420M |
| 2031 | ~$900M | ~($40M) | ~$860M |
Cash Position
The $119M raise provides capital for:
Facility & Equipment
~$66M (Year 1)
Working Capital
~$20M
Operations
~$25M
Contingency
~$8M
Financial Milestones
First Revenue: 2027
Positive EBITDA: 2027
$100M Revenue: 2028
$500M Revenue: 2029
$1B Revenue: 2030
IPO Readiness: 2030
Summary
NuBatt's financial projections demonstrate strong growth from $50M (2027) to $2.85B (2031) with EBITDA margins expanding from 24.0% to 43.2%.
| Metric | 2027 | 2031 |
|---|---|---|
| Revenue | $50M | $2.85B |
| EBITDA | $12M | $1.23B |
| EBITDA Margin | 24.0% | 43.2% |
| Revenue CAGR | — | ~170% |
Key characteristics:
- Diversified Revenue: Six streams reduce single-market risk
- Improving Margins: Scale economics drive margin expansion
- Capital Efficiency: High CapEx early, then cash generative
- Conservative Assumptions: Projections based on achievable milestones
- Clear Exit Path: IPO target 2030 at $10B+ valuation
[End of Financial Projections]